Rebecca Bahn

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Clinical review 157: Pathophysiology of Graves' ophthalmopathy: the cycle of disease
    Rebecca S Bahn
    Division of Endocrinology, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 88:1939-46. 2003
  2. pmc Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies
    Teck Kim Khoo
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Thyroid 17:1013-8. 2007
  3. pmc A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy
    Seema Kumar
    Division of Pediatric Endocrinology and Metabolism Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    J Mol Endocrinol 46:155-63. 2011
  4. pmc Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis
    Vishnu Sundaresh
    Division of Geriatrics and Primary Care Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 98:3671-7. 2013
  5. pmc A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy
    Adina F Turcu
    Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, 200 First Street Southwest, Rochester, Minnesota 55902, USA
    J Clin Endocrinol Metab 98:2153-9. 2013
  6. pmc A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody
    Seema Kumar
    Division of Pediatric Endocrinology and Metabolism, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55902, USA
    J Clin Endocrinol Metab 97:1681-7. 2012
  7. pmc Autoimmunity and Graves' disease
    R S Bahn
    Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic School of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Clin Pharmacol Ther 91:577-9. 2012
  8. doi request reprint Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists
    Rebecca S Bahn Chair
    Division of Endocrinology, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota 55905, USA
    Thyroid 21:593-646. 2011
  9. ncbi request reprint Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-associated ophthalmopathy
    Rebecca S Bahn
    Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Thyroid 12:193-5. 2002
  10. ncbi request reprint TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves' ophthalmopathy
    R S Bahn
    Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic, Rochester, MN 55905, USA
    J Endocrinol Invest 27:216-20. 2004

Collaborators

Detail Information

Publications35

  1. ncbi request reprint Clinical review 157: Pathophysiology of Graves' ophthalmopathy: the cycle of disease
    Rebecca S Bahn
    Division of Endocrinology, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 88:1939-46. 2003
  2. pmc Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies
    Teck Kim Khoo
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Thyroid 17:1013-8. 2007
    ..Although originally thought to represent another causative agent, antibodies to extraocular muscles are now generally thought to be secondary to extraocular muscle inflammation and damage...
  3. pmc A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy
    Seema Kumar
    Division of Pediatric Endocrinology and Metabolism Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    J Mol Endocrinol 46:155-63. 2011
    ..This antibody appears to act via the PI3K signaling cascade, suggesting that inhibition of PI3K signaling may represent a potential novel therapeutic approach in GO...
  4. pmc Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis
    Vishnu Sundaresh
    Division of Geriatrics and Primary Care Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 98:3671-7. 2013
    ..Several treatment options are available for Graves' disease (GD), including antithyroid drugs (ATDs), radioactive iodine (RAI), and thyroidectomy...
  5. pmc A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy
    Adina F Turcu
    Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, 200 First Street Southwest, Rochester, Minnesota 55902, USA
    J Clin Endocrinol Metab 98:2153-9. 2013
    ..A recently developed drug-like small molecule inverse agonist of TSHR, NCGC00229600, termed 1, binds to TSHR and blocks basal and stimulated signal transduction...
  6. pmc A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody
    Seema Kumar
    Division of Pediatric Endocrinology and Metabolism, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55902, USA
    J Clin Endocrinol Metab 97:1681-7. 2012
    ..The expansion of orbital tissues involves accumulation of hyaluronic acid (HA) within the orbit...
  7. pmc Autoimmunity and Graves' disease
    R S Bahn
    Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic School of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Clin Pharmacol Ther 91:577-9. 2012
    ..In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions...
  8. doi request reprint Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists
    Rebecca S Bahn Chair
    Division of Endocrinology, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota 55905, USA
    Thyroid 21:593-646. 2011
    ..This article describes evidence-based clinical guidelines for the management of thyrotoxicosis that would be useful to generalist and subspeciality physicians and others providing care for patients with this condition...
  9. ncbi request reprint Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-associated ophthalmopathy
    Rebecca S Bahn
    Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Thyroid 12:193-5. 2002
    ..Some of these may impact the expression of TSHr, the putative orbital autoantigen in this condition...
  10. ncbi request reprint TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves' ophthalmopathy
    R S Bahn
    Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic, Rochester, MN 55905, USA
    J Endocrinol Invest 27:216-20. 2004
    ..Alternately, locally enhanced expression of this protein at the sites of clinical disease may not be directly involved in pathogenesis, but could be secondary to the ongoing process, and nonetheless important in disease progression...
  11. ncbi request reprint Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy
    R S Bahn
    Division of Endocrinology, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 83:998-1002. 1998
    ..These results suggest that both the expression of this receptor and the accumulation of adipose tissue in the orbit in GO may be induced in vivo by a humoral factor(s) not present in the cell culture environment...
  12. ncbi request reprint Thyrotropin receptor expression in cultured Graves' orbital preadipocyte fibroblasts is stimulated by thyrotropin
    R S Bahn
    Division of Endocrinology, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Thyroid 8:193-6. 1998
    ..These studies suggest that the expression of this receptor in the orbit in vivo may be stimulated by TSH or other TSHr ligands, and that this stimulation may be important in the development of GO...
  13. ncbi request reprint Understanding the immunology of Graves' ophthalmopathy. Is it an autoimmune disease?
    R S Bahn
    Mayo Medical School, Rochester, Minnesota, USA
    Endocrinol Metab Clin North Am 29:287-96, vi. 2000
    ..Future studies using animal models and in vitro systems will allow definitive identification of the immune cell types, autoantigens, and autoantibodies involved in the pathogenesis of Graves' ophthalmopathy...
  14. ncbi request reprint Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor
    R W Valyasevi
    Division of Endocrinology, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 84:2557-62. 1999
    ..Furthermore, our studies support the concept that TSHr may be an important target antigen in this condition. Factors that stimulate adipocyte differentiation and TSHr expression in the orbit in GO have yet to be defined...
  15. ncbi request reprint Effect of tumor necrosis factor-alpha, interferon-gamma, and transforming growth factor-beta on adipogenesis and expression of thyrotropin receptor in human orbital preadipocyte fibroblasts
    R W Valyasevi
    Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic/Foundation, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 86:903-8. 2001
    ..In addition, the former two cytokines may play a role in determining the extent to which the volume of the orbital adipose tissue increases in this condition...
  16. ncbi request reprint Induction of leptin expression in orbital preadipocyte fibroblasts
    D Z Erickson
    Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic/Foundation, Rochester, Minnesota 55905, USA
    Thyroid 11:221-6. 2001
    ..This process would be expected to result in expansion of the orbital adipose tissues and increased TSHR expression within the orbit...
  17. ncbi request reprint Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy
    S C Jyonouchi
    Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Thyroid 11:929-34. 2001
    ..These findings suggest that IL-6 may play a role in the pathogenesis of GO by increasing expression of the putative autoantigen within the adipose/connective tissues of the orbit...
  18. doi request reprint Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies
    M A Frye
    Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA
    Acta Psychiatr Scand 120:10-3. 2009
    ..To assess the relationship between depressive relapse and change in thyroid function in an exploratory post hoc analysis from a controlled maintenance evaluation of bipolar I disorder...
  19. ncbi request reprint A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy
    C A Gorman
    Division of Endocrinology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ophthalmology 108:1523-34. 2001
    ..Although widely used for more than 85 years, the efficacy of radiotherapy for Graves' ophthalmopathy (GO) has not been established convincingly...
  20. ncbi request reprint A genomic point mutation in the extracellular domain of the thyrotropin receptor in patients with Graves' ophthalmopathy
    R S Bahn
    Department of Internal Medicine, Mayo Clinic Foundation, Rochester, Minnesota 55905
    J Clin Endocrinol Metab 78:256-60. 1994
    ..We suggest that the TSH receptor may be an important fibroblast autoantigen in GO and PTD, and that this mutant form of the receptor may have unique immunogenic properties...
  21. pmc Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor
    Seethalakshmi Iyer
    Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Endocrinol Metab 26:281-9. 2012
    ..Future therapies for this condition may involve inhibition of thyrotropin receptor signaling in orbital fibroblasts...
  22. ncbi request reprint Normal function in vivo of a homozygotic polymorphism in the human thyrotropin receptor
    R M Cuddihy
    Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Thyroid 5:255-7. 1995
    ....
  23. pmc Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy
    Seema Kumar
    Division of Pediatric Endocrinology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 89:930-5. 2004
    ....
  24. ncbi request reprint Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts
    Rosanee W Valyasevi
    Division of Endocrinology, Metabolism, and Nutrition, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 87:2352-8. 2002
    ..It is possible that endogenous PPARgamma ligands play a role in stimulating orbital adipogenesis in GO, and that future treatments may be aimed at antagonism of various components of the PPARgamma signaling system...
  25. ncbi request reprint Retinal microvascular abnormalities in patients treated with external radiation for graves ophthalmopathy
    Dennis M Robertson
    Department of Ophthalmology, Division of Endocrinology, Mayo Clinic, Rochester, MN 55905, USA
    Arch Ophthalmol 121:652-7. 2003
    ..Radiation was directed to the orbits of 42 affected patients using 0.2 rad (20 Gy) delivered in 10 doses of 0.02 rad (2 Gy). Patients were periodically examined during a 3-year interval...
  26. ncbi request reprint Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with graves' ophthalmopathy
    Seema Kumar
    Division of Pediatric Endocrinology, Clinic, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 88:4246-50. 2003
    ..In addition, the overexpression of IFN-gamma, without evidence of IL-4 or IL-5 expression, supports the concept that cell-mediated, rather than humoral, immunity plays the predominant role in pathogenesis of this disorder...
  27. ncbi request reprint Current perspective on the pathogenesis of Graves' disease and ophthalmopathy
    Bellur S Prabhakar
    Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois 60612 7344, USA
    Endocr Rev 24:802-35. 2003
    ..Collectively, recent studies have led to a better understanding of the pathogenesis of GD and GO and have opened up potential new avenues for developing novel treatments for GD and GO...
  28. ncbi request reprint How perceived physician leadership behavior affects physician satisfaction
    Ronald Menaker
    Administrative Services, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:983-8. 2008
    ....
  29. ncbi request reprint The impact of overt and subclinical hyperthyroidism on skeletal muscle
    Michael D Brennan
    Division of Endocrinology, Diabetes, Nutrition and Metabolism, Mayo Clinic, Rochester, Minnesota 55905, USA
    Thyroid 16:375-80. 2006
    ..This may have clinical relevance as SCH patients are often elderly and may therefore have concurrent sarcopenia of aging and would represent a previously unrecognized complication of SCH...
  30. pmc Thyroid transcription factor-1 in orbital adipose tissues: potential role in orbital thyrotropin receptor expression
    Kalyan K Bhattacharyya
    Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota 55905, USA
    Thyroid 15:422-6. 2005
    ..The presence of mRNA encoding TTF-1 in orbital tissues and cultures suggest that this transcription factor may play an important role in extrathyroidal, as it does in thyroidal, TSHR expression...
  31. pmc Gene expression profiling of orbital adipose tissue from patients with Graves' ophthalmopathy: a potential role for secreted frizzled-related protein-1 in orbital adipogenesis
    Seema Kumar
    Division of Pediatric Endocrinology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 90:4730-5. 2005
    ..The signs and symptoms of Graves' ophthalmopathy (GO) result from inflammation and increased volume of the orbital adipose tissues and extraocular muscles...
  32. ncbi request reprint Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland
    Dimitrios Karantanis
    Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Nucl Med 48:896-901. 2007
    ..Our purpose was to determine the clinical significance of diffusely increased (18)F-FDG uptake in the thyroid gland as an incidental finding on PET/CT...
  33. ncbi request reprint Optic neuropathy of Graves disease: results of transantral orbital decompression and long-term follow-up in 215 patients
    Cacia V Soares-Welch
    Division of Endocrinology, Diabetes, Metabolism, Nutrition and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Ophthalmol 136:433-41. 2003
    ..To review demographic characteristics, clinical features, and long-term outcomes of patients with optic neuropathy of Graves disease after transantral orbital decompression...
  34. ncbi request reprint The aftermath of orbital radiotherapy for graves' ophthalmopathy
    Colum A Gorman
    Department of Medicine, Mayo Clinic, Rochester, Minnesota Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ophthalmology 109:2100-7. 2002
    ....
  35. ncbi request reprint Effects of reducing the upper limit of normal TSH values
    Vahab Fatourechi
    JAMA 290:3195-6. 2003

Research Grants19

  1. Thyrotropin Receptor Auto Antibodies in Graves' Ophthalmopathy
    Rebecca Bahn; Fiscal Year: 2007
    ..Our studies will yield information concerning mechanisms involved in disease development, and will determine the effectiveness of a novel approach to therapy. ..
  2. EYE IN GRAVES DISEASE--ROLE OF ORBITAL FIBROBLASTS
    Rebecca Bahn; Fiscal Year: 2002
    ..The main goal of the research program is to increase understanding of the orbital immune response in GO in order that novel and more specific therapeutic and preventive strategies for this condition might be developed. ..
  3. EYE IN GRAVES DISEASE--ROLE OF ORBITAL FIBROBLASTS
    Rebecca Bahn; Fiscal Year: 2003
    ..The main goal of the research program is to increase understanding of the orbital immune response in GO in order that novel and more specific therapeutic and preventive strategies for this condition might be developed. ..
  4. EYE IN GRAVES DISEASE--ROLE OF ORBITAL FIBROBLASTS
    Rebecca Bahn; Fiscal Year: 2004
    ..The main goal of the research program is to increase understanding of the orbital immune response in GO in order that novel and more specific therapeutic and preventive strategies for this condition might be developed. ..
  5. Thyrotropin Receptor Auto Antibodies in Graves' Ophthalmopathy
    Rebecca Bahn; Fiscal Year: 2009
    ..Our studies will yield information concerning mechanisms involved in disease development, and will determine the effectiveness of a novel approach to therapy. ..
  6. Thyrotropin Receptor Auto Antibodies in Graves' Ophthalmopathy
    Rebecca S Bahn; Fiscal Year: 2010
    ..Our studies will yield information concerning mechanisms involved in disease development, and will determine the effectiveness of a novel approach to therapy. ..
  7. EYE IN GRAVES DISEASE--ROLE OF ORBITAL FIBROBLASTS
    Rebecca Bahn; Fiscal Year: 2001
    ..The main goal of the research program is to increase understanding of the orbital immune response in GO in order that novel and more specific therapeutic and preventive strategies for this condition might be developed. ..
  8. EYE IN GRAVES DISEASE--ROLE OF ORBITAL FIBROBLASTS
    Rebecca Bahn; Fiscal Year: 2000
    ..The main goal of the research program is to increase understanding of the orbital immune response in GO in order that novel and more specific therapeutic and preventive strategies for this condition might be developed. ..
  9. EYE IN GRAVES' DISEASE--ROLE OF ORBITAL FIBROBLASTS
    Rebecca Bahn; Fiscal Year: 1993
    ..The investigators believe these studies will enhance their understanding of disease pathogenesis which will translate into improve management strategies and eventually better clinical outcomes...
  10. EYE IN GRAVES' DISEASE--ROLE OF ORBITAL FIBROBLASTS
    Rebecca Bahn; Fiscal Year: 1992
    ..The investigators believe these studies will enhance their understanding of disease pathogenesis which will translate into improve management strategies and eventually better clinical outcomes...
  11. EYE IN GRAVES' DISEASE--ROLE OF ORBITAL FIBROBLASTS
    Rebecca Bahn; Fiscal Year: 1991
    ..The investigators believe these studies will enhance their understanding of disease pathogenesis which will translate into improve management strategies and eventually better clinical outcomes...
  12. EYE IN GRAVES DISEASE--ROLE OF ORBITAL FIBROBLASTS
    Rebecca Bahn; Fiscal Year: 1999
    ..The main goal of the research program is to increase understanding of the orbital immune response in GO in order that novel and more specific therapeutic and preventive strategies for this condition might be developed. ..
  13. Thyrotropin Receptor Auto Antibodies in Graves' Ophthalmopathy
    Rebecca S Bahn; Fiscal Year: 2010
    ..Our studies will yield information concerning mechanisms involved in disease development, and will determine the effectiveness of a novel approach to therapy. ..